Prevalence of female sexual dysfunction in gynecologic and urogynecologic patients according to the international consensus classification

Geiss, Ingrid; Umek, Wolfgang; Dungl, Andrea; Sam, Christine; Riss, P; Hanzal, Engelbert

doi:10.1016/s0090-4295(03)00487-4

Cited by 74 publications

(51 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been previously shown that 96% of women participating in a prevalence study for FSD with a 94% response rate were not embarrassed to fill out the survey concerning sexual activity and function [4]. This indicates that some urogynecologist have a wrong image of their patient's feelings with regard to enquiring about sexual experience.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Female sexual dysfunction: are urogynecologists ready for it?

et al. 2008

View full text Add to dashboard Cite

The aim of this study was to assess the practice of members of the British Society of Urogynaecology (BSUG) with respect to female sexual dysfunction (FSD) and compare it to members of the American Urogynecologic Society (AUGS). A web-based anonymous electronic questionnaire was sent to all (n = 150) BSUG members. Frequencies of responses and chi-square test for association with demographics were calculated. One hundred questionnaires were returned of which 95 were sufficiently filled. Fifty percent regularly screened for FSD at clinic visits and 49.5% after surgery, compared to 77% and 76% of AUGS members, respectively. The most important barrier was lack of time. Only 2% said FSD was not an important problem. Seventy-six percent found training for FSD unsatisfactory. FSD is not part of normal practice for half of BSUG members. There is, therefore, a need for better implementation of education and training at both undergraduate and postgraduate levels.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Fifty percent of sexually active women attending a gynecology outpatient clinic [4] and up to 64% of sexually active women attending a urogynecology clinic suffer from FSD [5]. Recent literature on FSD after pelvic floor surgery is inconclusive with regards to outcome.…”

Section: Introductionmentioning

confidence: 99%

Female sexual dysfunction: are urogynecologists ready for it?

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Salonia et al 14 reported on a high prevalence of FSD in women with lower urinary tract symptoms and urinary incontinence suggesting that assessment of FSD is warranted in these women. Geiss et al 15 reported on a high prevalence of FSD in gynaecologic and urogynaecologic patients.…”

Section: Discussionmentioning

confidence: 99%

Is the metabolic syndrome a risk factor for female sexual dysfunction in sexually active women?

Ponholzer

Temml²,

Rauchenwald

et al. 2007

Int J Impot Res

View full text Add to dashboard Cite

Despite of the high prevalence, pathogenesis of female sexual dysfunction (FSD) is still poorly understood. A consecutive series of sexually active women underwent a health investigation and completed a questionnaire on FSD. Metabolic syndrome (MS) was defined according to the International Diabetes Federation definition. A total of 538 women with a mean age of 44 years (range: 30-69) was analysed. The premenopausal group comprised 329 women (61.2%) with a mean age of 38.5 years; the postmenopausal cohort contained 209 women (38.8%) with a mean age of 52.7 years. In the total cohort (n ¼ 538) MS was present in 17.6%, 8.5% in the premenopausal group and 32.6% in the postmenopausal women. In premenopausal women, the MS was an independent risk factor for impaired sexual desire (P ¼ 0.03) with an age-adjusted odds ratio of 3.3 (95% confidence interval: 1.5-7.3). In premenopausal female sexual life, the MS represents an independent role via its correlation to impaired desire.

show abstract

“…HSDD is obviously of multi-factorial origin and androgen deficiency is not part of its definition. If we were to base the indication for androgen therapy in women on the presence of HSDD, we would start to treat a large proportion of the general population, with recent figures indicating a 50% incidence of female sexual dysfunction based on the AFUD criteria in gynecologic and uro-gynecologic out-patient cohorts (16). The presence of HSDD alone is certainly no justification for the initiation of androgen treatment.…”

Section: Definition Of Female Androgen Deficiencymentioning

confidence: 99%

Androgen therapy in women

Arlt

2006

eur j endocrinol

105

View full text Add to dashboard Cite

Androgens in women either derive from direct ovarian production or from peripheral conversion of the adrenal sex steroid precursor, dehydroepiandrosterone, towards active androgens. Therefore, loss of adrenal or ovarian function, caused by Addison's disease or consequent to bilateral oophorectomy, results in severe androgen deficiency, clinically often associated with a loss of libido and energy. Importantly, physiological menopause does not necessarily lead to androgen deficiency, as androgen synthesis in the ovaries may persist despite the decline in estrogen production. However, the definition of female androgen deficiency, as recently provided by the Princeton consensus statement, is not precise enough and may lead to over-diagnosis due to the high prevalence of its diagnostic criteria: androgen levels below or within the lower quartile of the normal range and concurrent sexual dysfunction. Importantly, physiological menopause is not necessarily associated with androgen deficiency and therefore does not routinely require androgen therapy. Current replacement options include transdermal testosterone administration or dehydroepiandrosterone treatment, both of which have been shown to result in significant improvements, in particular in libido and mood, while effects on body composition and muscular function are not well documented. It is important to keep in mind that the number of randomized controlled trials is still limited and that currently none of the available preparations is officially approved for use in women. Currently, androgen replacement should be reserved for women with severe androgen deficiency due to an established cause and matching clinical signs and symptoms.

show abstract

Prevalence of female sexual dysfunction in gynecologic and urogynecologic patients according to the international consensus classification

Cited by 74 publications

References 25 publications

Female sexual dysfunction: are urogynecologists ready for it?

Female sexual dysfunction: are urogynecologists ready for it?

Is the metabolic syndrome a risk factor for female sexual dysfunction in sexually active women?

Androgen therapy in women

Contact Info

Product

Resources

About